Odyssey Group International’s Planned Acquisition of Concussion Drug from Prevacus, Inc. Enhances Delivery Capabilities with Nasal Therapeutic
Odyssey Group International is circulating a video to better define its drug candidate PRV-002, a therapeutic compound drug to treat concussion (mild traumatic brain injury (mTBI), from UF Innovate | Sid Martin Biotech alum Prevacus Inc. Odyssey is expected to acquire PRV-002 by the end of February.
